ArticleScientific reports2025
Spatial gene expression profiling reveals the distinct microenvironment of tuberous sclerosis complex-associated angiomyolipoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The aim of this study was to characterize the transcriptional landscape of tuberous sclerosis complex-associated renal angiomyolipomas (TSC-AMLs) using spatial transcriptomics and to compare it with sporadic AMLs and renal cell carcinoma (RCC) to identify TSC-specific molecular features. Spatial gene expression analysis (CytAssist Visium) was performed on formalin-fixed, paraffin-embedded sections from one case each of TSC-AML, sporadic AML, and RCC. Unsupervised clustering revealed that TSC-AML and sporadic AML, unlike RCC, displayed triphasic tumor structures with vascular, smooth muscle, and adipose components expressing canonical perivascular epithelioid cell markers such as PMEL, MLANA, ACTB, and DES. TSC1 and TSC2 were downregulated, and mild upregulation of MTOR, MLST8, and RPTOR was observed, consistent with mTORC1 hyperactivation, whereas RCC showed broader pathway activation. Spatial pathway analysis indicated shared differentiation programs in smooth muscle regions but unique angiogenesis, extracellular matrix remodeling (Wnt and NABA matrisome), and lipid metabolic (PPAR signaling) enrichment in TSC-AML. Comparative profiling identified 42 genes uniquely upregulated in TSC-AML, including GRIA2, FABP4, and IL33, defining candidate TSC-AML-enriched features. Despite the single-case design, this pilot study provides hypothesis-generating insights into TSC-associated renal tumorigenesis and highlights potential biomarkers for future investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.